Protocol REVERSE-Long COVID-19 With Baricitinib Study (REVERSE-LC)

If anyone has specific comments on this trial design/protocol, you can post here, and I can forward to Jaime—I don’t think this train has left the station yet.

 

Immunomodulation in Long Covid

https://www.youtube.com/watch?v=H9jj7Hs_FJU

Haven’t watched yet.

 

From Chat GPT video summarizer (not sure how this works, but it works!)


### Summary of "Prof. E. Wesley Ely: Immunomodulation in Long Covid (Day 1, Block 4)"

- **Introduction and Speaker Background**:
- Dr. Wes Ely, a leading internist, pulmonologist, and critical care physician at Vanderbilt University.
- Co-director of the Critical Illness, Brain Dysfunction, and Survivorship Center.
- Notable research on ICU-acquired brain disease and delirium.

- **Presentation Highlights**:
- Dr. Ely discusses the Reverse LC Study, focusing on immunomodulation as a pathway to discovery for long Covid.
- Describes the story of a young man, a post-graduate student and near-concert pianist, who developed severe long Covid symptoms affecting his daily life and academic pursuits.

- **Long Covid and Research Efforts**:
- Emphasizes the importance of not abandoning long Covid patients and accompanying them with the best science.
- Discusses involvement in the National Academy of Medicine's efforts to redefine long Covid and improve research definitions.

- **Reverse LC Clinical Trial**:
- Details about the Phase III NIH-sponsored clinical trial of immunomodulation in long Covid.
- Enrollment to begin soon, with sites including Minnesota, Nashville, Emory in Atlanta, and UCSF.
- Collaboration with notable scientists like Akiko Iwasaki from Yale.

- **Historical Context and Drug Development**:
- Origin of the study from early AI predictions identifying baricitinib as a potential treatment for acute Covid.
- Previous successful trials showing baricitinib's effectiveness when combined with steroids in improving survival rates.

- **Trial Specifics**:
- Involves a high-touch study with comprehensive testing and patient monitoring.
- Patients will receive either placebo or baricitinib daily for six months and will be followed for a year.
- Aimed at understanding the effects of immunomodulation on brain fog and other long Covid symptoms.

- **Scientific Rationale**:
- Baricitinib’s role as an antiviral and immunomodulator, impacting various immune system components.
- The trial seeks to determine if this drug can alleviate symptoms by modulating the immune response without significant risks.

- **Ethics and Future Research**:
- Emphasis on conducting the study without financial conflicts of interest.
- Future plans to explore additional studies, including those involving Metformin.

- **Q&A Session**:
- Discussion on topics such as viral replication, interferon therapy, and inclusion of post-vaccine syndrome patients in future studies.

For more information, visit the [UniteToFight channel](https://www.youtube.com/UniteToFight).

---

If you found this summary useful, please consider sharing it with others. Doing so will help GPT reach more people and continue to improve. Thank you!
[Click here to share GPT on Twitter / X](https://bit.ly/3SbQ7jI)